Dr Scardino podcast - unique new Pca genes, new HT therapies et al

Thread view:

Enable EMail Alerts

Start New Thread

Thread rating:

MikeHi@anon.co.uk - 12 Apr 2008 19:54 GMT

I don't think this has been posted before? Fascinating Peter Scardino
podcast. My short broad layman notes: Current hormone therapy drugs
are relatively weak. They turn from being antagonist to agonist in
relatively short time. Their time is coming to an end. Exceptional new
genes found in Pca cells - 'we've never found such a common
chromosomal aberration', which could show way (five years) for new HT
drugs which don't become agonist (for newbies 'agonist' = encouraging
the disease). My other comment. In all these podcasts, as a layman I
find that Dr Neil Love the mediator asks questions which always
further illuminate. His knowledge seems to range in depth over every
podcast interviewee on this site. This is by way of my thanks to him.

I would be interested in seeing others' comments on the podcast. I
heard it to confirm anti-androgen therapy as 'a logical step' but
basically ineffective. Scardino even asks the question (which I have
read in this NG as a given), does it prolong life?

Scardino podcast http://tiny.cc/mlcbF

My sincere best wishes to all
MikeHi

Reply to this Message

Steve Jordan - 12 Apr 2008 23:50 GMT

On April 12, MikeHi wrote:

> ..........Fascinating Peter Scardino podcast.

Not having a iPod, I reckon it's out of my reach.

(snip)

> ..................'we've never found such a common
> chromosomal aberration', which could show way (five years) for new HT
> drugs which don't become agonist (for newbies 'agonist' = encouraging
> the disease).

(snip)

Beg to differ. That is a mischaracterization of an "agonist."

Here is the definition, per the Medline Plus Medical Dictionary:

"a chemical substance (as a drug) capable of combining with a receptor
on a cell and initiating the same reaction or activity typically
produced by the binding of an endogenous substance..."

Luteinizing hormone releasing hormone (LHRH) agonists, for example
Trelstar, Lupron and Zoladex, prevent testicular production of
testosterone. They do not "encourage" the relevant disease, prostate cancer.

More can be learned on the Prostate Cancer Research Institute site,
http://prostate-cancer.org/index.html

Regards,

Steve J

Reply to this Message

Steve Kramer - 12 Apr 2008 23:57 GMT

> On April 12, MikeHi wrote:
>
>> ..........Fascinating Peter Scardino podcast.
>
> Not having a iPod, I reckon it's out of my reach.

Just listened to it on my PC. Try it. Very interesting disucussion and
encouraging news for new ADT that does not go refractive.

Reply to this Message

MikeHi@anon.co.uk - 13 Apr 2008 11:06 GMT

I wrote On April 12, :
...Fascinating Peter Scardino podcast
...in which he said:.

>(snip)
>
[quoted text clipped - 4 lines]
>
>(snip)

>Beg to differ. That is a mischaracterization of an "agonist."
>
[quoted text clipped - 14 lines]
>
>Steve J

Sorry for the scientific clanger and thanks for the correction. What
Scardino said, mentioning Casodex and Flutamide ( and one other I
didn't catch) and anti-androgens in general was that, you respond,
but then they they turn from being an antagonist to an agonist - "they
start stimulating", is his actual follow-up phrase.

Kind regards
Best wishes to all

MikeHi

Reply to this Message